Company / Operating Cash Flow per Share
NewAmsterdam Pharma Co N.V. Operating Cash Flow per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.25
FY2025
5-year range
-$2.69 / $0.56
FY2021-FY2025
Trend
+25.7%
vs FY2024
Sector context
#123 of 208
Health Care
What the data says
At $-1.25, NewAmsterdam Pharma Co N.V.'s operating cash flow per share ranks #123 of 208 in the Health Care sector. Improved from $-1.72 to $-1.25 over the past 2 years.
Based on SEC 10-K filings.
-1.25 in FY2025.
Improved from $-1.72 to $-1.25 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#123 of 208 in Health CareTop 59% of 208This company -$1.25 Sector average -$21.21
▼
+94.1% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 25.7% year-over-year.
- Ranks #123 out of 208 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2022.
- Lowest operating cash flow per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.25 | +25.7% |
| FY2024 | -$1.68 | +2.2% |
| FY2023 | -$1.72 | -405.7% |
| FY2022 | $0.56 | +120.9% |
| FY2021 | -$2.69 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026